MX2022015005A - Derivados de 7-pirazol-5-il-indol macrociclicos como inhibidores de mcl-1. - Google Patents
Derivados de 7-pirazol-5-il-indol macrociclicos como inhibidores de mcl-1.Info
- Publication number
- MX2022015005A MX2022015005A MX2022015005A MX2022015005A MX2022015005A MX 2022015005 A MX2022015005 A MX 2022015005A MX 2022015005 A MX2022015005 A MX 2022015005A MX 2022015005 A MX2022015005 A MX 2022015005A MX 2022015005 A MX2022015005 A MX 2022015005A
- Authority
- MX
- Mexico
- Prior art keywords
- mcl
- inhibitors
- macrocyclic
- pyrazol
- indole derivatives
- Prior art date
Links
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title abstract 2
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- UULFYKOEVQAAOU-UHFFFAOYSA-N N1N=CC=C1C1=CC=CC2=C1NC=C2 Chemical class N1N=CC=C1C1=CC=CC2=C1NC=C2 UULFYKOEVQAAOU-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se relaciona con agentes farmacéuticos útiles para terapia y/o profilaxis en un sujeto, composición farmacéutica que comprende tales compuestos y su uso como inhibidores de MCL-1, útiles para tratar enfermedades tales como cáncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20177468 | 2020-05-29 | ||
| EP20203934 | 2020-10-26 | ||
| PCT/EP2021/064162 WO2021239862A1 (en) | 2020-05-29 | 2021-05-27 | Macrocyclic 7-pyrazol-5-yl-indole derivatives as inhibitors of mcl-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022015005A true MX2022015005A (es) | 2023-01-04 |
Family
ID=76217863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022015005A MX2022015005A (es) | 2020-05-29 | 2021-05-27 | Derivados de 7-pirazol-5-il-indol macrociclicos como inhibidores de mcl-1. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230265105A1 (es) |
| EP (1) | EP4157852A1 (es) |
| JP (1) | JP2023526985A (es) |
| KR (1) | KR20230017823A (es) |
| CN (1) | CN115605486A (es) |
| AU (1) | AU2021278292A1 (es) |
| BR (1) | BR112022024117A2 (es) |
| CA (1) | CA3178283A1 (es) |
| MX (1) | MX2022015005A (es) |
| WO (1) | WO2021239862A1 (es) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2400371T3 (es) | 2005-07-07 | 2013-04-09 | Abbott Laboratories | Promotores de la apoptosis |
| PL2134685T3 (pl) | 2007-04-16 | 2016-02-29 | Abbvie Inc | Pochodne indolu niepodstawione w pozycji 7 jako inhibitory Mcl-1 |
| NZ579833A (en) | 2007-04-16 | 2012-11-30 | Abbott Lab | 7-substituted indole mcl-1 inhibitors |
| TWI742074B (zh) | 2016-04-22 | 2021-10-11 | 瑞典商阿斯特捷利康公司 | Mcl-1抑制劑及其使用方法 |
| JP7013389B2 (ja) * | 2016-05-19 | 2022-01-31 | バイエル アクチェンゲゼルシャフト | 大環状インドール誘導体 |
| TWI781996B (zh) | 2017-03-31 | 2022-11-01 | 瑞典商阿斯特捷利康公司 | 合成ｍｃｌ-１抑制劑之方法 |
| TW201904976A (zh) | 2017-03-31 | 2019-02-01 | 瑞典商阿斯特捷利康公司 | Ｍｃｌ-１抑制劑及其使用方法 |
| BR112021004805A2 (pt) | 2018-09-30 | 2021-06-01 | Jiangsu Hengrui Medicine Co., Ltd. | derivado macrocíclico de indol, método de preparação do mesmo e aplicação do mesmo na medicina |
| WO2020103864A1 (en) | 2018-11-22 | 2020-05-28 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic indoles as mcl-1 inhibitors |
| WO2020151738A1 (en) | 2019-01-23 | 2020-07-30 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic fused pyrrazoles as mcl-1 inhibitors |
| MX2021010321A (es) | 2019-03-08 | 2021-11-17 | Zeno Man Inc | Compuestos macrociclicos. |
-
2021
- 2021-05-27 WO PCT/EP2021/064162 patent/WO2021239862A1/en unknown
- 2021-05-27 CN CN202180035723.3A patent/CN115605486A/zh active Pending
- 2021-05-27 EP EP21729291.1A patent/EP4157852A1/en active Pending
- 2021-05-27 CA CA3178283A patent/CA3178283A1/en active Pending
- 2021-05-27 BR BR112022024117A patent/BR112022024117A2/pt unknown
- 2021-05-27 MX MX2022015005A patent/MX2022015005A/es unknown
- 2021-05-27 US US17/998,957 patent/US20230265105A1/en active Pending
- 2021-05-27 AU AU2021278292A patent/AU2021278292A1/en active Pending
- 2021-05-27 JP JP2022572284A patent/JP2023526985A/ja active Pending
- 2021-05-27 KR KR1020227045398A patent/KR20230017823A/ko active Search and Examination
Also Published As
| Publication number | Publication date |
|---|---|
| US20230265105A1 (en) | 2023-08-24 |
| CA3178283A1 (en) | 2021-12-02 |
| JP2023526985A (ja) | 2023-06-26 |
| BR112022024117A2 (pt) | 2022-12-27 |
| WO2021239862A1 (en) | 2021-12-02 |
| EP4157852A1 (en) | 2023-04-05 |
| CN115605486A (zh) | 2023-01-13 |
| AU2021278292A1 (en) | 2023-02-09 |
| KR20230017823A (ko) | 2023-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022000390A (es) | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. | |
| PH12021551274A1 (en) | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors | |
| MX2023000438A (es) | Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1. | |
| MX2021015770A (es) | Inhibidores macrociclicos de mcl-1. | |
| MX2022015813A (es) | 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1. | |
| SG10201810401RA (en) | Pharmaceutical combinations for treating cancer | |
| MX2022005298A (es) | Compuestos intermediarios de sintesis de inhibidores de a2a. | |
| MX2021012501A (es) | Inhibidores de complejo represivo polycomb 2 (prc2). | |
| SA519402103B1 (ar) | 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط | |
| PH12020500665A1 (en) | Pladienolide derivatives as spliceosome targeting agents for treating cancer | |
| PH12020500666A1 (en) | Pladienolide compounds and their use | |
| MX2023008677A (es) | Derivados de urolitinas y métodos para su uso. | |
| MX2022006853A (es) | Macrociclos para uso en el tratamiento de enfermedades. | |
| MX2022006180A (es) | Derivados macrociclicos de sulfonilo como inhibidores de mcl-1. | |
| MX2022006179A (es) | Derivados macrociclicos de indol como inhibidores de mcl-1. | |
| MX2022015005A (es) | Derivados de 7-pirazol-5-il-indol macrociclicos como inhibidores de mcl-1. | |
| MX2022010299A (es) | Derivados macrocíclicos de indol como inhibidores de mcl-1. | |
| MX2023007297A (es) | 3-fluoro-but-3-enamidas ramificadas macrociclicas como inhibidores de mcl-1. | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| MX2023003516A (es) | Inhibidores no covalentes de la cinasa dependiente de ciclina 7 (cdk7). | |
| MX2022016004A (es) | Desderivados de 7-(pirazol-5-il)-indol macrociclicos enlazados a n como inhibidores de mcl-1. | |
| MX2022016179A (es) | Compuestos y metodos para tratar infecciones fungicas. | |
| MX2022015998A (es) | Derivados de 4-(pirazol-5-il)-indol macrocíclico unidos a n como inhibidores de mcl-1. | |
| MX2023007291A (es) | Derivados de 4-(pirazol-5-il)-indol macrociclicos ramificados como inhibidores de mcl-1. | |
| MX2020013805A (es) | Derivados de piridopirimidinona para uso como inhibidores de axl. |